LEXARIA BIOSCIENCE C

Item 7.01 Regulation FD Disclosure.

On November 5, 2020 Lexaria Bioscience Corp. provided an outline of its planned
strategic initiatives for 2021 whereby the focus of its business will be on the
out-licensing of its patented DehydraTECH drug delivery technology within four
core areas of business:

· Heart disease including hypertension utilizing CBD;

· Reduced-risk methods of delivering non-combusted nicotine;

· Improving antiviral drug delivery for applications that include Covid-19,
influenza, herpes, hepatitis and AIDS; and

· Hemp-based CBD business-to-business ("B2B") applications for
non-pharmaceutical consumer and therapeutic or medicinal products and
prospective pharmaceutical indications beyond hypertension.

Item 9.01 Financial Statements And Exhibits.

Exhibit No. Description

99.1 Press Release issued November 5, 2020





2

© Edgar Online, source Glimpses